2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 证券代码：300434 证券简称：金石亚药 公告编号：2025-020 四川金石亚洲医药股份有限公司 2、现场会议召开地点：杭州市滨江区江南大道 4760 号亚科中心公司会议室 3、会议召开方式：本次股东大会采取现场投票和网络投票相结合的方式 4、会议召集人：公司第五届董事会 5、会议主持人：公司董事长马益平先生 6、会议召开的合法、合规性：2025 年 4 月 23 日，公司第五届董事会第八 次会议审议通过《关于召开 2024 年年度股东大会的议案》，决议召开本次股东大 会，本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 （二）会议的出席情况 1、会议召开的时间 （1）现场会议召开时间：2025 年 5 月 23 日（星期五）下午 2：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 23 ...

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]

Group 1 - The chemical pharmaceutical sector experienced a significant rally, with Hendi Pharmaceutical (301211) rising over 10% [1] - Xinhua Pharmaceutical (000756) reached its daily limit up [1] - Other companies such as Jinshi Yiyao (300434), Haichuang Pharmaceutical, and Duori Pharmaceutical (301075) also saw increases [1]

Financial Performance - In 2024, the company achieved operating revenue of 1.102 billion yuan, a year-on-year decrease of 8.84% [5] - The net profit attributable to shareholders was 91.76 million yuan, down 27.29% year-on-year [5] - The basic earnings per share were 0.23 yuan per share [5] Key Financial Ratios - The net cash inflow from operating activities was 158 million yuan, an increase of 4.6% year-on-year [4] - The weighted average return on equity was 3.75%, a decrease of 1.65 percentage points year-on-year [4] - The gross profit margin was 57.44%, down 6.44% year-on-year [4] - The asset-liability ratio stood at 19.16%, and the net profit margin was 8.03% [4] Business Segment Performance - The core product "Kuaike" series in the cold medicine segment accounted for 55.49% of revenue but saw a year-on-year decline of 17.16% due to shrinking retail demand and competition from foreign products [4] - Revenue from health food and traditional Chinese medicine slices was 39.09 million yuan, down 7.98% year-on-year, with the new product "Jinxing Glucosamine Soft Capsule" not yet achieving scale [4] - Revenue from complete production lines was 147 million yuan, marking a significant year-on-year increase of 89.95% [4] Research and Development - In 2024, the company's R&D investment was 49.99 million yuan, accounting for 4.54% of revenue [6] - The consistency evaluation for Diclofenac Sodium Sustained-Release Tablets has entered the application stage, and the antiviral drug Oseltamivir Phosphate Capsules have been approved for market [6] - The company plans to accelerate the promotion of "Jinxing Glucosamine Soft Capsule" through e-commerce channels [6] Dividend Distribution - The company plans to distribute a cash dividend of 0.69 yuan per 10 shares (including tax) in 2024 [7] International Expansion - The mechanical segment is providing customized magnetron sputtering vacuum coating equipment to global clients, with a factory planned in Mexico to enhance hydrogen pipeline technology output capabilities [6]

Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]

Core Viewpoint - Sichuan Jinshi Asia Pharmaceutical Co., Ltd. (referred to as "Jinshi Asia Pharmaceutical" or "the company") reported a decline in both revenue and net profit for the fiscal year 2024 and the first quarter of 2025, primarily due to intensified competition in the cold medicine market and changes in medical policies [1][2]. Financial Performance - In 2024, the company achieved total revenue of 1.102 billion yuan, a year-on-year decrease of 8.84%, and a net profit of 91.76 million yuan, down 27.29% [1]. - For the first quarter of 2025, revenue was 291 million yuan, reflecting a 19.65% decline year-on-year, while net profit was 62.85 million yuan, a decrease of 30.02% [1][2]. Market Dynamics - The cold medicine market has become increasingly competitive, with a diverse range of products including traditional cold medicines, Chinese herbal medicines, and imported antiviral drugs, which has intensified market competition [1][2]. - The shift in patient treatment preferences towards hospital care during the 2024 flu season has led to a significant reduction in retail sales of cold medicines [2]. Business Structure - The company's reliance on the cold medicine category has exacerbated revenue volatility, as its core product line, the "Kuaike" cold medicine series, has seen a decline in demand following a period of heightened consumption [2]. - Despite attempts to diversify into health products and prescription drugs, these new business segments have not yet contributed significantly to overall revenue [2]. Product Concentration - Jinshi Asia Pharmaceutical's main business includes the research, production, and sales of over 90 drug production approvals and 7 health food production approvals, with the Kuaike cold medicine series being a major revenue source [3]. - The concentration of leading products in specific market segments provides a competitive advantage, but any adverse changes in raw material prices or market conditions could significantly impact the company's performance [3].

证券代码：300434 证券简称：金石亚药 公告编号：2025-016 四川金石亚洲医药股份有限公司 关于聘任证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五届董事会第八次会议，审议通过了《关于聘任证券事务代表的议案》。 同意聘任易盛兰女士（简历附后）为公司证券事务代表，与公司证券事务代表王 莹女士共同协助董事会秘书履行职责，任期与公司本届董事会任期一致。 易盛兰女士已取得深圳证券交易所董事会秘书资格证书，具备与其行使职权 相应的任职条件，不存在《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》规定的不得 担任上市公司证券事务代表的情形。 公司证券事务代表易盛兰女士联系方式如下： 传 真：028-85628208 电子信箱：goldstone@gsap-group.com 特此公告。 附件：易盛兰女士简历 四川金石亚洲医药股份有限公司 董 事 会 二〇二五年四月二十五日 联系人：易盛兰 联 ...

四川金石亚洲医药股份有限公司 2024 年度监事会工作报告 2024 年，四川金石亚洲医药股份有限公司（以下简称"公司"）监事会， 严格依照《公司法》、《证券法》等法律法规，以及《公司章程》、《监事会议事 规则》的有关规定认真履行监督职责，依法独立行使职权，对公司的生产经营、 重大事项、财务状况、内部控制、信息披露、关联交易以及董事、高级管理人 员履行职责等方面进行了有效的审查和监督，切实维护公司和股东的合法权益。 现将 2024 年度监事会主要工作汇报如下： （二）检查财务和定期报告审核情况 报告期内，监事会定期对公司的财务状况和财务制度等进行监督和检查。 监事会认为：公司财务制度健全，财务体系运作规范，财务状况良好，不存在 控股股东及关联方非经营性资金占用或违规对外担保的情况；公司编制的财务 报表能够客观反映公司的财务状况和经营成果，定期报告内容真实、准确、完 整，不存在任何虚假记载、误导性陈述或者重大遗漏。立信会计师事务所（特 殊普通合伙）出具的审计报告真实、公允地反映了公司 2024 年度的财务状况和 经营成果，对审计报告无异议。 （三）公司内部控制情况 一、 2024 年度监事会工作情况 报告期内， ...

四川金石亚洲医药股份有限公司 2024 年度财务决算报告 一、年度财务报告及审计情况 公司聘请立信会计师事务所（特殊普通合伙）审计公司及其子公司的 2024 年度财务报表， 包括 2024 年 12 月 31 日的资产负债表和合并资产负债表、2024 年度的利润表和合并利润表，2024 年度现金流量表和合并现金流量表，以及财务报表附注。立信会计师事务所（特殊普通合伙）对 上述审计范围内的公司均出具了标准无保留意见的审计报告。 如无特殊说明，下述描述和数据均为合并口径，单位：人民币元。 二、2024 年度公司主要财务指标 | 项 目 | 2024 年 | 2023 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,102,354,866.43 | 1,209,199,438.06 | -8.84% | | 归属于上市公司股东的净利润（元） | 91,761,833.80 | 126,199,723.64 | -27.29% | | 归属于上市公司股东的扣除非经常性损益的净利润 | 82,294,435.98 | 114,113,258.00 | -27. ...

四川金石亚洲医药股份有限公司 关于举行 2024 年度网上业绩说明会的公告 证券代码：300434 证券简称：金石亚药 公告编号：2025-018 四川金石亚洲医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司(以下简称"公司")《2024 年年度报告》及 其摘要已于 2025 年 4 月 25 日披露，为使投资者进一步了解公司的财务状况、经 营情况及公司发展规划，公司将于 2025 年 5 月 16 日(星期五)15:00-17:00 在全景 网举行金石亚药 2024 年度网上业绩说明会，本次说明会将采用网络远程方式举 行，投资者可登陆全景网"投资者关系互动平台"(https://ir.p5w.net/)参与本次业 绩说明会。 出席本次说明会的人员有：董事长、总经理马益平，董事、副总经理、董事 会秘书林强，副总经理王志昊，财务总监王庆国，独立董事刘初旺。 为充分尊重投资者，提升交流的针对性，现就公司金石亚药 2024 年度网上 业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者 可于 2025 ...